The composition of the pulmonary microbiota in sarcoidosis - an observational study
The composition of the pulmonary microbiota in sarcoidosis - an observational study
复制标题
DOI：
10.1186/s12931-019-1013-2
复制
发表时间：
2019-02-28
影响因子：
5.8
通讯作者：
Bals, Robert
中科院分区：
文献类型：
--
作者：
Becker, Andre;Vella, Giovanna;Bals, Robert
结节病是一种病因不明的全身性疾病。疾病机制在很大程度上是推测的，可能包括启动和驱动潜在免疫过程的微生物模式的作用。本研究的目的是研究结节病患者肺部微生物区系的特征，并将其组成和多样性与其他间质性肺病(ILD)患者和既往健康对照组的结果进行比较。方法PULMOHOM研究纳入患者(结节病，n=31；间质性肺病，n=19)，这是一项前瞻性队列研究，旨在描述肺部疾病的炎症过程。对肺中叶或舌叶进行支气管镜检查，并立即将回收的液体送往肺内进行16sRNA基因测序分析。结果结节病患者和其他ILDS患者在微生物组组成和多样性方面没有显著差异。另外，Atopobium属、梭杆菌属、分枝杆菌属和丙酸杆菌属的丰度在两组间也无差异。结论基于16sRNA基因测序的肺微生物区系分析显示，与其他ILD患者相比，结节病患者并未出现明显的生物失调。这些数据不排除结节病发病机制中的微生物成分。
BackgroundSarcoidosis is a systemic disease of unknown etiology. The disease mechanisms are largely speculative and may include the role microbial patterns that initiate and drive an underlying immune process. The aim of this study was to characterize the microbiota of the lung of patients with sarcoidosis and compare its composition and diversity with the results from patients with other interstitial lung disease (ILD) and historic healthy controls.MethodsPatients (sarcoidosis, n=31; interstitial lung disease, n=19) were recruited within the PULMOHOM study, a prospective cohort study to characterize inflammatory processes in pulmonary diseases. Bronchoscopy of the middle lobe or the lingula was performed and the recovered fluid was immediately sent for analysis of the pulmonary microbiota by 16sRNA gene sequencing. Subsequent bioinformatic analysis was performed to compare the groups.ResultsThere were no significant differences between patients with sarcoidosis or other ILDs with regard to microbiome composition and diversity. In addition, the abundance of the genera Atopobium, Fusobacterium, Mycobacterium or Propionibacterium were not different between the two groups. There were no gross differences to historical healthy controls.ConclusionThe analysis of the pulmonary microbiota based on 16sRNA gene sequencing did not show a significant dysbiosis in patients with sarcoidosis as compared to other ILD patients. These data do not exclude a microbiological component in the pathogenesis of sarcoidosis.